The DOI matches its Crossref record; 5 of the 6 references it cites were found in a registry or an index.
Drug-Induced Graves Disease From CTLA-4 Receptor Suppression
Abstract
Monoclonal antibody, ipilimumab, useful for treatment of metastatic melanoma, blocks CTLA-4 mediated T-cell suppression and can also cause a Graves ophthalmopathy like syndrome. Epidemiologic study has linked variant polymorphisms of CTLA-4 receptor gene to the presence of thyroid eye disease. The combination of these observations suggests CTLA-4 mediated T-cell functions are important to the pathogenesis of thyroid-associated eye disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To the best of our knowledge at the time of writing, only nine cases of ICPi-induced Graves’ hyperthyroidism and seven cases of induced Graves’ orbitopathy have been described in the literature, associated with anti-PD-1 or anti-CTLA-4 treatment or their combination (Table 3), with only one patient presenting with both thyrotoxicosis and orbitopathy [19,29,30,31,35,36,37,38,39,40,41,42,43,44].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [31]
In the citing paper
“In the literature, initially only induced Graves’ orbitopathy (GO) without thyrotoxicosis were described in patients undergoing Ipilimumab (anti-CTLA-4) treatment [29,30,31].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [31]
In the citing paper
“Human leukocyte antigen (HLA) haplotypes linked with classic T1D (DR3-DQ2 and DR4-DQ8) and fulminant diabetes in the Asian population (DR4-DQ4 and DR9-DQ9) are over-represented among ICI-DM patients68”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [68]
In the citing paper
“whereas reports of cases on CTLA-4 monotherapy are very rare”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [68]
In the citing paper
“Approximately 97% of all reported ICI-DM cases have arisen with anti-PD-1/PD-L1 or combination treated patients”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [68]
Citations
Cites
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population
Yanagawa, T., Hidaka, Y., Guimarães, V. C., Soliman, M., & DeGroot, L. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.1.7829637 · Cited by 464
Bashey, A., Medina, B., Corringham, S., Pasek, M., Carrier, E., Vrooman, L., Lowy, I., Solomon, S., Morris, L., Holland, H., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168468 · Cited by 343
Immunoregulatory and Susceptibility Genes in Thyroid and Polyglandular Autoimmunity
Dittmar, M., & Kahaly, G. J. (2005) · Thyroid · doi:10.1089/thy.2005.15.239 · Cited by 66
Naik, V. M., Khadavi, N. M., Naik, M. N., Hwang, C. J., Goldberg, R. A., Tsirbas, A., Smith, T. J., & Douglas, R. S. (2008) · Thyroid · doi:10.1089/thy.2007.0403 · Cited by 37
Cited by
Sorted by citations
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,505
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685
Voskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 465
Endocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
Metadata
- Authors
- Borodic, G., Hinkle, D. M., & Cia, Y.
- Affiliations
- Massachusetts Eye and Ear Infirmary (US)
- Harvard University (US)
- Corresponding author
- Borodic, Gary
- ORCID
- Hinkle, David M.
- Venue
- Ophthalmic Plastic & Reconstructive Surgery
- Published
- 2011-07
- Volume
- 27
- Issue
- 4
- Pages
- e87-e88
- ISSN
- 0740-9303 (ISSN-L)
- OpenAlex
- W1988822265
- Cited by
- 120
- References
- 6
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 7 · 2021: 9 · 2020: 9 · 2019: 13 · 2018: 13 · 2017: 7 · 2016: 13 · 2015: 10 · 2014: 4 · 2013: 10 · 2012: 2
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Ophthalmic Plastic and Reconstructive Surgery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Keywords
- ipilimumab, CTLA-4 blockade, Graves' ophthalmopathy, T cell suppression, metastatic melanoma, CTLA-4 gene polymorphism, autoimmune thyroid disease
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Antineoplastic Agents, Diplopia, Exophthalmos, Female, Humans, Lung Neoplasms, Magnetic Resonance Imaging, Melanoma, Middle Aged, Neoplasms, Unknown Primary, Oculomotor Muscles, Antigens, CD, Graves Ophthalmopathy, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
